Quantitative and qualitative methods of evaluating response to biologics in severe asthma patients: Results from a real-world study
[EN] Asthma is a complex major noncommunicable disease affecting around 333 million people worldwide, both children and adults.New biological therapies for treating severe asthma have remarkably improved disease management. Notwith-standing, one remaining crucial problem is evaluating the response t...
| Autores: | , , , , , , , , |
|---|---|
| Tipo de recurso: | artículo |
| Estado: | Versión publicada |
| Fecha de publicación: | 2023 |
| País: | España |
| Institución: | Universidad de Salamanca (USAL) |
| Repositorio: | GREDOS. Repositorio Institucional de la Universidad de Salamanca |
| OAI Identifier: | oai:gredos.usal.es:10366/158778 |
| Acceso en línea: | http://hdl.handle.net/10366/158778 |
| Access Level: | acceso abierto |
| Palabra clave: | asthma biologics Benralizumab Dupilumab Mepolizumab Genetics Allergy and Immunology 3207.01 Alergias 2409 Genética alergia e inmunología genética |
| Sumario: | [EN] Asthma is a complex major noncommunicable disease affecting around 333 million people worldwide, both children and adults.New biological therapies for treating severe asthma have remarkably improved disease management. Notwith-standing, one remaining crucial problem is evaluating the response to these treatments. Therefore, adequate measurement of the response to biologics in a holistic manner that integrates clinical variables of interest and quality of life is needed, particularly in identifying super-responder patients (SR). Menzies-Gow et al went more profound in the concept and proposed a consensus to evaluate remission. |
|---|